The generic-drug group was ranked No. 2 out of the 197 industries tracked by IBD on Monday, so it’s little wonder that three of its members made the 16-stock Spotlight screen. Akorn (AKRX), arguably the top stock in the industry, is nearing a 55.96 buy point of an irregularly shaped cup base. Its relative strength line is hitting a new high — a bullish sign as the stock approaches its own new high.